NASDAQ:LENS - Presbia Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$0.5510 -0.03 (-5.16 %)
(As of 01/21/2019 06:00 AM ET)
Previous Close$0.5510
Today's Range$0.55 - $0.61
52-Week Range$0.28 - $5.50
Volume27,917 shs
Average Volume50,645 shs
Market Capitalization$9.45 million
P/E RatioN/A
Dividend YieldN/A
Beta1.92
Presbia PLC, an ophthalmic device company, develops and markets optical lens implants for treating presbyopia. The company provides the refractive lens for patient surgeries, as well as accessories for procedures. It primarily operates in South Korea, Australia, New Zealand, Italy, the Netherlands, Ireland, Canada, and Germany. The company was founded in 2014 and is headquartered in Dublin, Ireland.

Receive LENS News and Ratings via Email

Sign-up to receive the latest news and ratings for LENS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:LENS
CUSIPN/A
Phone353-551-1487

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$10,000.00
Book Value$0.18 per share

Profitability

Net Income$-16,990,000.00

Miscellaneous

Employees24
Market Cap$9.45 million
OptionableNot Optionable

Presbia (NASDAQ:LENS) Frequently Asked Questions

What is Presbia's stock symbol?

Presbia trades on the NASDAQ under the ticker symbol "LENS."

How were Presbia's earnings last quarter?

Presbia PLC (NASDAQ:LENS) posted its earnings results on Friday, August, 12th. The medical instruments supplier reported ($0.32) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.25) by $0.07. The medical instruments supplier had revenue of $0.01 million for the quarter, compared to the consensus estimate of $0.04 million. View Presbia's Earnings History.

When is Presbia's next earnings date?

Presbia is scheduled to release their next quarterly earnings announcement on Tuesday, February 12th 2019. View Earnings Estimates for Presbia.

What price target have analysts set for LENS?

1 Wall Street analysts have issued 12-month price objectives for Presbia's shares. Their predictions range from $6.00 to $6.00. On average, they expect Presbia's share price to reach $6.00 in the next year. This suggests a possible upside of 988.9% from the stock's current price. View Analyst Price Targets for Presbia.

What is the consensus analysts' recommendation for Presbia?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Presbia in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Presbia.

What are Wall Street analysts saying about Presbia stock?

Here are some recent quotes from research analysts about Presbia stock:
  • 1. According to Zacks Investment Research, "Presbia PLC offers ophthalmic device. It is focused on the development and marketing of an optical lens implant for the treatment of presbyopia. The company's product consists of Presbia Flexivue Microlens(TM). Presbia PLC is based in Irvine, California. " (9/27/2018)
  • 2. HC Wainwright analysts commented, "Valuation methodology, risks and uncertainties. We utilize a discounted cash flow-based net present value (NPV) approach to value Presbia. This yields a total value of $160M for the Flexivue Microlens product, using a 20% discount rate, 50% manufacturing and marketing offset, and a 12.5% tax rate as Presbia is domiciled in Ireland." (8/27/2018)

Has Presbia been receiving favorable news coverage?

News headlines about LENS stock have been trending somewhat negative recently, InfoTrie Sentiment Analysis reports. InfoTrie rates the sentiment of news coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Presbia earned a news sentiment score of -1.4 on InfoTrie's scale. They also assigned media headlines about the medical instruments supplier a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the next several days.

Who are some of Presbia's key competitors?

Who are Presbia's key executives?

Presbia's management team includes the folowing people:
  • Mr. Vladimir Feingold, Consultant (Age 70)
  • Mr. Mark T. Yung, CEO & Chairman (Age 45)
  • Mr. Richard T. Fogarty, Chief Accounting Officer, VP of Fin. & Sec. (Age 68)
  • Ms. Casey Jean Lind, Chief Operating Officer (Age 57)
  • Ms. Marie Cha, Director of Direct Response Marketing

When did Presbia IPO?

(LENS) raised $50 million in an initial public offering (IPO) on Thursday, January 29th 2015. The company issued 4,200,000 shares at $11.00-$13.00 per share. Jefferies served as the underwriter for the IPO.

How do I buy shares of Presbia?

Shares of LENS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Presbia's stock price today?

One share of LENS stock can currently be purchased for approximately $0.5510.

How big of a company is Presbia?

Presbia has a market capitalization of $9.45 million and generates $10,000.00 in revenue each year. Presbia employs 24 workers across the globe.

What is Presbia's official website?

The official website for Presbia is http://www.presbia.com.

How can I contact Presbia?

Presbia's mailing address is SANDYFORD OFFICE CENTRE SUITE 7 17 CORRIG ROAD, DUBLIN 18 L2, . The medical instruments supplier can be reached via phone at 353-551-1487.


MarketBeat Community Rating for Presbia (NASDAQ LENS)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  132 (Vote Outperform)
Underperform Votes:  126 (Vote Underperform)
Total Votes:  258
MarketBeat's community ratings are surveys of what our community members think about Presbia and other stocks. Vote "Outperform" if you believe LENS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe LENS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/21/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel